262 related articles for article (PubMed ID: 23007406)
1. Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia.
Yang JJ; Cheng C; Devidas M; Cao X; Campana D; Yang W; Fan Y; Neale G; Cox N; Scheet P; Borowitz MJ; Winick NJ; Martin PL; Bowman WP; Camitta B; Reaman GH; Carroll WL; Willman CL; Hunger SP; Evans WE; Pui CH; Loh M; Relling MV
Blood; 2012 Nov; 120(20):4197-204. PubMed ID: 23007406
[TBL] [Abstract][Full Text] [Related]
2. Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia.
Yang JJ; Cheng C; Yang W; Pei D; Cao X; Fan Y; Pounds SB; Neale G; Treviño LR; French D; Campana D; Downing JR; Evans WE; Pui CH; Devidas M; Bowman WP; Camitta BM; Willman CL; Davies SM; Borowitz MJ; Carroll WL; Hunger SP; Relling MV
JAMA; 2009 Jan; 301(4):393-403. PubMed ID: 19176441
[TBL] [Abstract][Full Text] [Related]
3. Association of GATA3 Polymorphisms With Minimal Residual Disease and Relapse Risk in Childhood Acute Lymphoblastic Leukemia.
Zhang H; Liu AP; Devidas M; Lee SH; Cao X; Pei D; Borowitz M; Wood B; Gastier-Foster JM; Dai Y; Raetz E; Larsen E; Winick N; Bowman WP; Karol S; Yang W; Martin PL; Carroll WL; Pui CH; Mullighan CG; Evans WE; Cheng C; Hunger SP; Relling MV; Loh ML; Yang JJ
J Natl Cancer Inst; 2021 Apr; 113(4):408-417. PubMed ID: 32894760
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide study of methotrexate clearance replicates SLCO1B1.
Ramsey LB; Panetta JC; Smith C; Yang W; Fan Y; Winick NJ; Martin PL; Cheng C; Devidas M; Pui CH; Evans WE; Hunger SP; Loh M; Relling MV
Blood; 2013 Feb; 121(6):898-904. PubMed ID: 23233662
[TBL] [Abstract][Full Text] [Related]
5. Clinical utility of sequential minimal residual disease measurements in the context of risk-based therapy in childhood acute lymphoblastic leukaemia: a prospective study.
Pui CH; Pei D; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Bhojwani D; Gruber TA; Leung WH; Downing JR; Evans WE; Relling MV; Campana D
Lancet Oncol; 2015 Apr; 16(4):465-74. PubMed ID: 25800893
[TBL] [Abstract][Full Text] [Related]
6. In vivo response to methotrexate forecasts outcome of acute lymphoblastic leukemia and has a distinct gene expression profile.
Sorich MJ; Pottier N; Pei D; Yang W; Kager L; Stocco G; Cheng C; Panetta JC; Pui CH; Relling MV; Cheok MH; Evans WE
PLoS Med; 2008 Apr; 5(4):e83. PubMed ID: 18416598
[TBL] [Abstract][Full Text] [Related]
7. Methylene tetrahydrofolate reductase gene polymorphism in Egyptian children with acute lymphoblastic leukemia.
Tantawy AA; El-Bostany EA; Adly AA; Abou El Asrar M; El-Ghouroury EA; Abdulghaffar EE
Blood Coagul Fibrinolysis; 2010 Jan; 21(1):28-34. PubMed ID: 19923983
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP1A1, GSTP1 and XRCC1 genes polymorphisms on toxicity and response to chemotherapy in childhood acute lymphoblastic leukemia.
Abo-Bakr A; Mossallam G; El Azhary N; Hafez H; Badawy R
J Egypt Natl Canc Inst; 2017 Sep; 29(3):127-133. PubMed ID: 28844589
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.
Rocha JC; Cheng C; Liu W; Kishi S; Das S; Cook EH; Sandlund JT; Rubnitz J; Ribeiro R; Campana D; Pui CH; Evans WE; Relling MV
Blood; 2005 Jun; 105(12):4752-8. PubMed ID: 15713801
[TBL] [Abstract][Full Text] [Related]
10. Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
Banklau C; Jindadamrongwech S; Sawangpanich R; Apibal S; Hongeng S; Paisooksantivatana K; Pakakasama S
Hematol Oncol Stem Cell Ther; 2010; 3(3):103-8. PubMed ID: 20890066
[TBL] [Abstract][Full Text] [Related]
11. Association of an inherited genetic variant with vincristine-related peripheral neuropathy in children with acute lymphoblastic leukemia.
Diouf B; Crews KR; Lew G; Pei D; Cheng C; Bao J; Zheng JJ; Yang W; Fan Y; Wheeler HE; Wing C; Delaney SM; Komatsu M; Paugh SW; McCorkle JR; Lu X; Winick NJ; Carroll WL; Loh ML; Hunger SP; Devidas M; Pui CH; Dolan ME; Relling MV; Evans WE
JAMA; 2015 Feb; 313(8):815-23. PubMed ID: 25710658
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.
Pui CH; Pei D; Raimondi SC; Coustan-Smith E; Jeha S; Cheng C; Bowman WP; Sandlund JT; Ribeiro RC; Rubnitz JE; Inaba H; Gruber TA; Leung WH; Yang JJ; Downing JR; Evans WE; Relling MV; Campana D
Leukemia; 2017 Feb; 31(2):333-339. PubMed ID: 27560110
[TBL] [Abstract][Full Text] [Related]
13. Genetics of ancestry-specific risk for relapse in acute lymphoblastic leukemia.
Karol SE; Larsen E; Cheng C; Cao X; Yang W; Ramsey LB; Fernandez CA; McCorkle JR; Paugh SW; Autry RJ; Lopez-Lopez E; Diouf B; Jeha S; Pui CH; Raetz EA; Winick NJ; Carroll WL; Hunger SP; Loh ML; Devidas M; Evans WE; Yang JJ; Relling MV
Leukemia; 2017 Jun; 31(6):1325-1332. PubMed ID: 28096535
[TBL] [Abstract][Full Text] [Related]
14. Association of initial response to prednisone treatment in childhood acute lymphoblastic leukaemia and polymorphisms within the tumour necrosis factor and the interleukin-10 genes.
Lauten M; Matthias T; Stanulla M; Beger C; Welte K; Schrappe M
Leukemia; 2002 Aug; 16(8):1437-42. PubMed ID: 12145682
[TBL] [Abstract][Full Text] [Related]
15. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study.
Borowitz MJ; Devidas M; Hunger SP; Bowman WP; Carroll AJ; Carroll WL; Linda S; Martin PL; Pullen DJ; Viswanatha D; Willman CL; Winick N; Camitta BM;
Blood; 2008 Jun; 111(12):5477-85. PubMed ID: 18388178
[TBL] [Abstract][Full Text] [Related]
16. ARID5B genetic polymorphisms contribute to racial disparities in the incidence and treatment outcome of childhood acute lymphoblastic leukemia.
Xu H; Cheng C; Devidas M; Pei D; Fan Y; Yang W; Neale G; Scheet P; Burchard EG; Torgerson DG; Eng C; Dean M; Antillon F; Winick NJ; Martin PL; Willman CL; Camitta BM; Reaman GH; Carroll WL; Loh M; Evans WE; Pui CH; Hunger SP; Relling MV; Yang JJ
J Clin Oncol; 2012 Mar; 30(7):751-7. PubMed ID: 22291082
[TBL] [Abstract][Full Text] [Related]
17. Polymorphisms within glutathione S-transferase genes (GSTM1, GSTT1, GSTP1) and risk of relapse in childhood B-cell precursor acute lymphoblastic leukemia: a case-control study.
Stanulla M; Schrappe M; Brechlin AM; Zimmermann M; Welte K
Blood; 2000 Feb; 95(4):1222-8. PubMed ID: 10666194
[TBL] [Abstract][Full Text] [Related]
18. Germline genetic variation in an organic anion transporter polypeptide associated with methotrexate pharmacokinetics and clinical effects.
Treviño LR; Shimasaki N; Yang W; Panetta JC; Cheng C; Pei D; Chan D; Sparreboom A; Giacomini KM; Pui CH; Evans WE; Relling MV
J Clin Oncol; 2009 Dec; 27(35):5972-8. PubMed ID: 19901119
[TBL] [Abstract][Full Text] [Related]
19. Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study.
Chen IM; Harvey RC; Mullighan CG; Gastier-Foster J; Wharton W; Kang H; Borowitz MJ; Camitta BM; Carroll AJ; Devidas M; Pullen DJ; Payne-Turner D; Tasian SK; Reshmi S; Cottrell CE; Reaman GH; Bowman WP; Carroll WL; Loh ML; Winick NJ; Hunger SP; Willman CL
Blood; 2012 Apr; 119(15):3512-22. PubMed ID: 22368272
[TBL] [Abstract][Full Text] [Related]
20. Minimal residual disease values discriminate between low and high relapse risk in children with B-cell precursor acute lymphoblastic leukemia and an intrachromosomal amplification of chromosome 21: the Austrian and German acute lymphoblastic leukemia Berlin-Frankfurt-Munster (ALL-BFM) trials.
Attarbaschi A; Mann G; Panzer-Grümayer R; Röttgers S; Steiner M; König M; Csinady E; Dworzak MN; Seidel M; Janousek D; Möricke A; Reichelt C; Harbott J; Schrappe M; Gadner H; Haas OA
J Clin Oncol; 2008 Jun; 26(18):3046-50. PubMed ID: 18565891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
